Download Poster (586.02 KB)

Publication
  • ASN •
  • 8 November, 2025 •
  • •

Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial

Carla M Nester, Fadi Fakhouri, Daniel P Gale, Andrew S Bomback, Christoph Licht, Giuseppe Remuzzi, Nicole CAJ Van de Kar, Katie Gordon, Anwesha Mukherjee, Johan Szamosi, Lucía Quintana-Gallardo, Matthew C Pickering

Available materials

Oral Presentation
Publication
  • ASN •
  • 7 November, 2025 •
  • •

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons

Bradley P Dixon, Andrew S Bomback, Carly Rich, Mingyi Huang, Piotr Wojciechowski, Rose Chang, Fernando Caravaca-Fontán, Fadi Fakhouri

Available materials

Poster
Publication
  • ASN •
  • 6 November, 2025 •
  • •

Management of Uncontrolled Gout Among Nephrology Professionals: Findings from a Medical Chart Audit

Hyon Choi, Nana Kragh, Amod Athavale, Bhavisha Desai, Amal Gulaid, Abiola Oladapo, Brittany Smith, Kenneth Saag

Available materials

Poster
Symposium
  • ESPN •
  • 17 October, 2025 •
  • •

Decoding complement in C3G and primary IC-MPGN Exploring evolving paths in care

Sally Johnson, Francesca Diomedi Camassei, Dieter Haffner

Available materials

Slides
Publication
  • ESPN •
  • 17 October, 2025 •
  • •

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary ​ IC-MPGN: Phase 3 VALIANT study results

Christoph Licht, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Nayoa Fujita, Larry A Greenbaum, Antonio Mastrangelo, Nabil Melhem, Nicole CAJ Van de Kar, Marina Vivarelli, Dean Wallace, Virginia Taliadouros, Johan Szamosi, Katie Gordon, Zhongshen Wang, Carla M Nester

Available materials

Oral Presentation
Publication
  • ESPN •
  • 16 October, 2025 •
  • •

Pegcetacoplan for paediatric patients with​ C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Nicole CAJ Van de Kar, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Larry A Greenbaum, Christoph Licht, Antonio Mastrangelo, Nabil Melhem, Nayoa Fujita, Dean Wallace, Marina Vivarelli, Zhongshen Wang, Dima Decker, Johan Szamosi, Lucía Quintana-Gallardo, Carla M Nester

Available materials

Oral Presentation
Publication
  • IPTA •
  • 18 September, 2025 •
  • •

Pegcetacoplan for post-transplant patients with complement 3 glomerulopathy or primary (idiopathic) immune-complex membranoproliferative glomerulonephritis: an analysis of the phase 2 NOBLE and phase 3 VALIANT trials

Andrew S Bomback, David Kavanagh, Daniel Zecher, Julien Zuber, Ondrej Vicklicky, Li Li, Luis López Lázaro, Fadi Fakhouri

Available materials

Poster
Sign up for alerts